Journal article
Safety and efficacy of ticagrelor versus clopidogrel for carotid artery stenting: propensity score matched analysis
- Abstract:
- Background: Dual antiplatelet therapy (DAPT) is recommended around carotid artery stenting (CAS) to reduce periprocedural stroke risk. Clopidogrel is widely used, but response variability related to pharmacokinetics and CYP2C19 polymorphisms may limit its effectiveness. Ticagrelor is a more potent, direct acting P2Y12 inhibitor, but its comparative effectiveness in CAS remains uncertain. Methods: We conducted a retrospective cohort study in the TriNetX database, identifying adults with carotid artery stenosis who underwent CAS between January 2016 and August 2025 and received either ticagrelor or clopidogrel. Primary outcomes at 180 days included ischemic stroke, major hemorrhage, intracranial hemorrhage, and all cause mortality. Secondary outcomes included inpatient readmission and emergency department (ED) visits. Propensity score matching (1:1), Kaplan–Meier survival, and Cox proportional hazards analysis were used. Results: Among 6996 patients, 378 received ticagrelor and 6618 received clopidogrel; aspirin co-use was similar (89.7% vs 91.7%). After matching, 377 patients remained in each cohort. Ischemic stroke (2.7% vs 4.2%; HR 0.56, 95% CI 0.25 to 1.27; P=0.159) and major hemorrhage (2.9% vs 4.8%; HR 0.61, 95% CI 0.29 to 1.30; P=0.197) were numerically lower with ticagrelor. Rates of intracranial hemorrhage were similar (2.7% vs 2.7%; HR 0.61, 95% CI 0.14 to 2.53; P=0.488). Mortality was numerically higher with ticagrelor (3.4% vs 2.7%; HR 1.64, 95% CI 0.68 to 3.97; P=0.263). ED visits were similar (14.3% vs 14.6%; HR 0.97, 95% CI 0.67 to 1.42; P=0.895). Inpatient readmission was numerically lower with ticagrelor (15.9% vs 19.1%; HR 0.81, 95% CI 0.57 to 1.14; P=0.223). Conclusion: Ticagrelor and clopidogrel showed comparable safety and effectiveness following CAS. Future prospective genotype informed trials are warranted to confirm these findings.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 278.6KB, Terms of use)
-
- Publisher copy:
- 10.1136/jnis-2025-024658
Authors
+ National Institute of General Medical Sciences
More from this funder
- Funder identifier:
- https://ror.org/04q48ey07
- Publisher:
- BMJ Publishing Group
- Journal:
- Journal of NeuroInterventional Surgery More from this journal
- Pages:
- jnis-2025-024658
- Article number:
- jnis-2025-024658
- Publication date:
- 2026-01-13
- Acceptance date:
- 2025-12-30
- DOI:
- EISSN:
-
1759-8486
- ISSN:
-
1759-8478
- Language:
-
English
- Keywords:
- Pubs id:
-
2358810
- UUID:
-
uuid_1e1e4b6c-c272-450d-bd89-ef37231430e8
- Local pid:
-
pubs:2358810
- Source identifiers:
-
3680995
- Deposit date:
-
2026-01-21
- ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.
Terms of use
- Copyright date:
- 2026
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from BMJ Publishing Group at https://doi.org/10.1136/jnis-2025-024658
If you are the owner of this record, you can report an update to it here: Report update to this record